Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma

被引：4

作者：

Schrenk, Karin G. ^{[1
]}

Weschenfelder, Wolfram ^{[2
]}

Spiegel, Christian ^{[2
]}

Agaimy, Abbas ^{[3
]}

Stoehr, Robert ^{[3
]}

Hartmann, Arndt ^{[3
]}

Gassler, Nikolaus ^{[4
]}

Drescher, Robert ^{[5
]}

Freesmeyer, Martin ^{[5
]}

Malouhi, Amer ^{[6
]}

Buerckenmeyer, Florian ^{[6
]}

Aschenbach, Rene ^{[6
]}

Teichgraeber, Ulf ^{[6
]}

Koegler, Christine ^{[7
]}

Vogt, Matthias ^{[8
]}

Hofmann, Gunther O. ^{[2
]}

Hochhaus, Andreas ^{[1
]}

机构：

[1] Univ Hosp Jena, Dept Hematol & Internal Oncol, Clin Internal Med 2, Klinikum 1, D-07747 Jena, Germany

[2] Univ Hosp Jena, Clin Trauma Hand & Reconstruct Surg, Jena, Germany

[3] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Inst Pathol, Erlangen, Germany

[4] Univ Hosp Jena, Inst Forens Med, Sect Pathol, Jena, Germany

[5] Univ Hosp Jena, Clin Nucl Med, Jena, Germany

[6] Univ Hosp Jena, Inst Diagnost & Intervent Radiol, Jena, Germany

[7] Malteser Hosp St Marien, Clin Gen & Visceral Surg, Erlangen, Germany

[8] Clin Medictr PartGmbB, Erlangen, Germany

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 09期

关键词：

RET-fusion; Sarcoma; Selpercatinib; Targeted therapy; TRIM33; EFFICACY; CANCERS;

D O I：

10.1007/s00432-022-04496-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET-fusion-associated sarcomas. As new targeted therapies are under development, similar treatment options may become available for sarcoma patients.

引用

页码：5493 / 5496

页数：4

共 50 条

[21] Outcomes of surgery and treatment with selective RET TK inhibitor Selpercatinib in children with MEN2 and advanced MTC
Kurzawinski, Tom
Hubbard, Jonathan
Aziz, Tarek Abdel
Butler, Colin
Gaze, Mark
Brain, Caroline
Marshall, Lynley
Shankar
BRITISH JOURNAL OF SURGERY, 2022, 109
[22] Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
Reingold, Rachel E.
Parisi, Rose
Harada, Guilherme
Moy, Andrea P.
Dranitsaris, George
Francis, Jasmine H.
Canestraro, Julia
Lester, Julia A.
Kaplanis, Lauren A.
Liu, Dazhi
Lacouture, Mario E.
Drilon, Alexander
JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (03):
[23] Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer
Huang, Yan
Dai, Shuang
Yin, Wenlian
Luo, Feng
Li, Yan
ONCOTARGETS AND THERAPY, 2023, 16 : 1015 - 1020
[24] Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion plus non-small-cell lung cancer (NSCLC).
Drilon, Alexander E.
Gautschi, Oliver
Besse, Benjamin
Subbiah, Vivek
Tan, Daniel Shao-Weng
Park, Keunchil
De Braud, Filippo G.
Alonso, Guzman
Wolf, Juergen
Soldatenkova, Victoria
French, Pearl Plernjit
Lin, Aimee K.
Goto, Koichi
Solomon, Benjamin J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] Primary RET-mutated lung neuroendocrine carcinoma in MEN2B: response to RET-targeted therapy
Geiger, Jessica L.
Chiosea, Simion I.
Challinor, Sue M.
Nikiforova, Marina N.
Bauman, Julie E.
ENDOCRINE-RELATED CANCER, 2015, 22 (05) : L19 - L22
[26] Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
Arora, Aakriti
Zaemes, Jacob
Ozdemirli, Metin
Kim, Chul
FRONTIERS IN ONCOLOGY, 2023, 13
[27] TAS0286/HM05, a novel potent and selective RET inhibitor, induced tumor regression in RET fusion positive model
Miyazaki, Isao
Fujita, Hidenori
Yamada, Yukari
Ishida, Keiji
Ito, Kenjirou
Matsuo, Kenichi
CANCER SCIENCE, 2018, 109 : 1002 - 1002
[28] BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion plus NSCLC and RET-mutant MTC: Phase 1 study results.
Schoffski, Patrick
Cho, Byoung Chul
Italiano, Antoine
Loong, Herbert H. F.
Massard, Christophe
Rodriguez, Laura Medina
Shih, Jin-Yuan
Subbiah, Vivek
Verlingue, Loic
Andreas, Karen
Basson, Craig T.
Clawson, Alicia
Ho, Peter T. C.
Knight, Shelley
Scheuber, Anita
Keegan, Mitchell
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients
Lu, Shun
Wang, Qiming
Wu, Lin
Xing, Ligang
Li, Yintao
Han, Liang
Dong, Xiaorong
Wei, Hongying
Xu, Wen
Li, Chuan
Yang, Liuqing
Wu, Qiong
CANCER RESEARCH, 2023, 83 (08)
[30] Real-World Outcomes of Selective RET Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two Databases
Liao, Chi-Yin
Gonzalez-Ferrer, Carmen
Whipple, Samuel
Peterson, Patrick M.
Barker, Scott S.
Bhandari, Naleen Raj
Wang, Feng
CANCERS, 2024, 16 (22)

← 1 2 3 4 5 →